Immunovant succeeds in Phase 2 clinical trial and Royivant launches LISRAYA commercially
IMVT Immunovant Inc
$35.15 +15.13%
View chart & analysis → - 1Immunovant achieved a 92.5% ACR20 response rate at week 28 in the 600mg dose group of its Phase 2 clinical trial.
- 2Royivant Sciences recorded $31 million in initial commercial sales for LISRAYA.
- 3Royivant confirmed cash holdings of $4.2 billion as of September 30.
So what's the key point?
Immunovant obtained a high response rate in drug trials, and Royivant's new drug has also begun generating sales. Royivant holds $4.2 billion in cash.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.